v3.26.1
Financial Instruments and Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:
Fair Value Measurement
Using Fair Value Hierarchy:
June 30,
2026		Level 1Level 2Level 3
Assets:
Equity securities$0.3 $0.3 $— $— 
$0.3 $0.3 $— $— 
Liabilities:
Deferred compensation liabilities$18.7 $— $18.7 $— 
Contingent consideration liabilities54.7 — — 54.7 
$73.4 $— $18.7 $54.7 
Fair Value Measurement
Using Fair Value Hierarchy:
December 31,
2025		Level 1Level 2Level 3
Assets:
Equity securities$10.5 $10.5 $— $— 
$10.5 $10.5 $— $— 
Liabilities:
Deferred compensation liabilities$21.7 $— $21.7 $— 
Contingent consideration liabilities54.8 — — 54.8 
$76.5 $— $21.7 $54.8 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table summarizes activity for contingent consideration:
Terlivaz CVR (1)
Edex (2)
Total
December 31, 2025$20.0 $34.8 $54.8 
Fair value adjustment— 1.2 1.2 
Payments— (1.3)(1.3)
June 30, 2026$20.0 $34.7 $54.7 
(1) Fair value classified within accrued and other current liabilities as of June 30, 2026 and December 31, 2025.
(2) Includes fair value of $2.9 million and $3.0 million as of June 30, 2026 and December 31, 2025, classified within accrued and other current liabilities, respectively.
Schedule of Carrying Amount and Fair Value of Long-Term Debt
June 30, 2026December 31, 2025
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
8.50% Senior Secured Notes due April 2031
$1,054.3 $1,054.0 $1,060.0 $1,058.1 
Level 2:
Term Loan due April 20311,479.3 1,477.4 1,487.3 1,472.0 
Total Debt$2,533.6 $2,531.4 $2,547.3 $2,530.1 
Schedules of Concentration of Risk
The following table shows net sales attributable to customers that accounted for 10.0% or more of the Company's total net sales:
Three Months EndedSix Months Ended
June 30,
2026		June 27,
2025		June 30,
2026		June 27,
2025
FFF Enterprises, Inc.39.8 %62.8 %37.3 %59.3 %
Cencora, Inc.19.0 *19.4 *
CVS Health Corporation12.9 *12.6 *
* Net sales to this customer were less than 10.0% of total net sales during the respective periods presented above.
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
June 30,
2026		December 31,
2025
Cencora, Inc.38.7 %47.5 %
FFF Enterprises, Inc.29.1 19.2